erythromycin ethyl succinate/sulfisoxazole (Eryzole, Pediazole, Sulfimycin)

Introduction

200 mg erythromycin ethylsuccinate (EES) & 600 mg sulfisoxazole per 5 mL.

Indications

• upper & lower respiratory tract infections
• otitis media
• other infections in patients allergic to penicillin

Contraindications

pregnancy-category C

safety in lactation -

Dosage

• adults:
  • 400 mg erythromycin/1200 mg sulfisoxazole every 6 hours
• children: 50 mg/kg/day (based on EES dose) PO divided QID

Pharmacokinetics

elimination: kidney > liver

Adverse effects

• common (> 10%)
  • abdominal pain, cramping, nausea/vomiting
• less common (1-10%)
  • hypersensitivity, cholestatic jaundice, phlebitis at site of injection, oral candidiasis
• uncommon (< 1%)
  • thrombophlebitis, hypertrophic pyloric stenosis, ventricular arrhythmias, fever, rash, diarrhea, eosinophilia, headache, Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, hepatic necrosis, toxic nephrosis, crystalluria

Drug interactions

• Pediazole increases effects & toxicity of:
  • warfarin, astemizole, terfenadine, loratadine, carbamazepine, cyclosporine, digoxin, theophylline

More general terms

• antibiotic combination

Components

• erythromycin ethyl succinate (EES, Pediamycin)
• sulfisoxazole (Gantrisin)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=84006